RxDoctor Payments Data

Alyssa Sandquist

Nurse Practitioner · Spokane, WANPI 1225538523

Payments from drug & device makers

$1,059in general payments, 2019–2025

Across 25 payments — averaging $42.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$270
  • Novartis$236
  • Abbott$152
  • Ancora Heart, Inc.$141
  • Boehringer Ingelheim$121
  • E.r. Squibb & Sons, L.L.C.$50
  • plus $89 from 5 others

What the payments were for

  • Food & beverage$1,059100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,059 in reported general payments places this provider in the 85th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$19,009
Medicare patients
101
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin132$91,650
EntrestoSacubitril/Valsartan87$67,705
EliquisApixaban30$19,887
Metoprolol Succinate134$2,340
Torsemide65$1,842
Potassium Chloride84$1,666
Eplerenone22$1,146
Spironolactone148$721
Hydralazine Hcl23$623
Mycophenolate Mofetil22$571
Atorvastatin Calcium58$555
Carvedilol41$388
Isosorbide Mononitrate ErIsosorbide Mononitrate19$349
Furosemide45$239
Rosuvastatin Calcium24$229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$121$91,650132 claims
NovartisEntresto$236$67,70587 claims
PfizerEliquis$14$19,88730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →